Tag:
Novartis
Latest Headlines
Latest Headlines
FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine
The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.
Russia hopes to lure drugmakers with increase in buying power
Russia has a lot of purchasing muscle, but few sellers when it comes to pharmaceuticals, so the government has a plan to lure them with a vast increase in the products it buys from local makers. The nation's officials are focusing on the foreign drugmakers to set up production plants in Russia as one way to emerge from a string of recessions.
UPDATED: Novartis' Alcon recalling more intraocular lenses in Japan due to reports of postoperative inflammation
Novartis' Alcon expanded the recall of its intraocular lenses in Japan, pushing the number of affected units to 89,042, due to a continued increase in reports of postoperative inflammation among patients who received the AcrySof IQ Toric lens.
JAMA: Valeant's 18-fold price hikes top widespread increases in dermatology prices
A new study shows that prices for 19 brand-name dermatology meds, including two from Valeant Pharmaceuticals, have increased almost fivefold, on average, over the past 6 years.
Novartis' Cosentyx price sets the stage for psoriasis battle
A revolution is happening in psoriasis treatment, and Novartis was the company to get it started with next-gen therapy Cosentyx, approved earlier this year. And the Swiss drugmaker in January set a list price it hoped would help turn the tide.
Novartis' Entresto gets the go-ahead in Europe
Novartis' blockbuster-in-waiting, Entresto, has been handed its second big approval. The new heart failure drug has snagged an OK from the European Commission.
Genmab's lymphoma project flops in Phase III with Novartis holding the bag
Genmab's plans to develop ofatumumab for lymphoma came to a halt as the company pulled the plug early on a Phase III trial that was unlikely to meet its goals, souring an investment from partner Novartis.
Novartis snags new approvals for Cosentyx in Europe
Novartis has been jockeying for additional uses for its next-gen psoriasis med, Cosentyx, hoping that a trifecta of indications will help generate blockbuster sales and distinguish the drug from its competition in a hot market. Now the med is moving one step closer toward achieving its blockbuster aspirations with an EU nod to treat patients with psoriatic arthritis and ankylosing spondylitis.
Advera Health: Novartis, GSK asthma meds linked to more side effects than Merck drugs
Bestselling asthma drugs from Novartis and respiratory behemoth GlaxoSmithKline are also showing more adverse events in post-marketing safety data than competing products from Merck, according to a new report, potentially presenting issues further down the line as companies duke it out for market share.
Novartis takes a third biosimilar shot at Amgen with a copy of the blockbuster Neulasta
Novartis is moving toward the U.S. market with a biosimilar of Amgen's Neulasta, awaiting FDA approval for a long-acting treatment designed to boost white blood cell count.
